Prospective Evaluation Of Oral Cannabis Extracts In Children With Epilepsy
Interest in cannabis as a treatment for people living with epilepsy has increased over the last several years. The use of cannabis for epilepsy has been described in anecdotal reports for centuries. [1 –3] Colorado voters passed a medicinal cannabis law allowing use for specific diagnoses in November 2000. Despite many new treatments becoming available in the last 20 years, including new antiseizure medications, neurostimulation, and improvements in surgical techniques and etiologic identificati on, many children living with epilepsy do not have well-controlled seizures.
Authors: Husain AM Abstract [Box: see text]. PMID: 31608668 [PubMed - as supplied by publisher]
Condition: Drug Resistant Epilepsy Interventions: Other: mindfulness intervention; Other: psycho educative programme Sponsor: University Hospital, Grenoble Not yet recruiting
We present the case of a 12-year-old girl with medically refractory epilepsy and a vagal nerve stimulator (VNS), who experienced severe obstructive sleep apnea (OSA) with respiratory events closely matching her VNS settings. We demonstrated a real-time decrease in OSA through an in-laboratory VNS titration study, decreasing her VNS frequency from 20 Hz to 10 Hz. We were able to demonstrate a baseline level of OSA by turning off the VNS. We then effectively treated her residual OSA with continuous positive airway pressure (CPAP). Novel to our case is that this in-laboratory VNS titration did not result in any subsequent inc...
AbstractStiripentol (Diacomit®) is an orally-active, structurally unique anti-epileptic drug (AED) with multiple potential mechanisms of action, including enhancement of central γ-aminobutyric acid transmission. In the EU, stiripentol is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with Dravet syndrome (DS; previously known as severe myoclonic epilepsy of infancy), whose seizu res are not adequately controlled with clobazam and valproate. This approval (and similar DS indications in the USA, Canada and Japan), reflec...
ConclusionsAll patients with severe autism had SPAs. However, they did not correlate with FDG-PET findings.
Conclusions: In>8 years of observation, most participants experienced a robust and sustained antidepressant response to SCC DBS. News in Context: Ethical issues raised around deep brain stimulation (DBS) research Closing the Circuit: Helen Mayberg’s research could revolutionize depression treatment Expo Day: Neuroenginnering, BPI, Arrowsmith Program &ARPF from SharpBrains
ConclusionThis review confirms that healthcare professionals should discus SUDEP with CYPwE and/or their caregivers at or around the time of diagnosis and that the discussion should include prevalence of SUDEP, risk factors and risk reduction methods relative to the individual concerned. Apart from delivering SUDEP information face-to-face, with written or online information provided to reinforce messages, there is a lack of evidence on “how” to impart this sensitive information. Further research exploring the most acceptable and effective methods of discussing SUDEP with CYPwE and their caregivers is therefore indicated.
Autoimmune encephalitis should be considered when patients with posterior reversible encephalopathy syndrome show atypical clinical courses.
Conclusions Respiratory complications are the leading nonseizure cause of 30-day unplanned readmissions in patients with generalized convulsive epilepsy and status epilepticus. Further research on identifying appropriate interventions to reduce readmissions from respiratory causes may improve outcomes for patients in these epilepsy subgroups.
ConclusionsThe findings of this study demonstrate that the proposed prediction strategy is suitable for the prediction of seizure onset.